Phase I|[sol]|II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

T Hoehler; G von Wichert; C Schimanski; S Kanzler; M H Moehler; A Hinke; T Seufferlein; J Siebler; A Hochhaus; D Arnold; M Hallek; R Hofheinz; U T Hacker

首页> 外文期刊>British Journal of Cancer >Phase I|[sol]|II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

【24h】

Phase I|[sol]|II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

机译：卡培他滨联合奥沙利铂联合贝伐单抗和伊马替尼治疗转移性结直肠癌的I | [sol] | II期临床试验：AIO KRK 0205

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer.

机译：背景：血小板源性生长因子受体β信号转导和血管内皮生长因子的联合抑制作用可在临床前模型中促进血管正常化，并可能导致化学疗法向肿瘤组织的递送增加。这项I / II期试验评估了卡培他滨联合奥沙利铂（XELOX）联合贝伐单抗和伊马替尼在转移性结直肠癌患者的一线治疗中的安全性和有效性。

著录项

来源
《British Journal of Cancer》 |2013年第6期|共6页
作者
T Hoehler; G von Wichert; C Schimanski; S Kanzler; M H Moehler; A Hinke; T Seufferlein; J Siebler; A Hochhaus; D Arnold; M Hallek; R Hofheinz; U T Hacker;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [J] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, BMC Cancer . 2011,第1期

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机，III期试验：AIO KRK 0110 Trial / ML22011试验
2. Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial [J] . Alexander Stein, Albrecht Kretzschmar, Dirk Behringer, BMC Cancer . 2013,第1期

机译：卡培他滨和贝伐单抗用于不可切除的转移性结直肠癌患者：II期AIO KRK 0105试验的最终结果
3. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - A randomized trial of the German AIO CRC study group [J] . MoosmannN., VonWeikersthalL.F., Vehling-KaiserU., Journal of Clinical Oncology . 2011,第8期

机译：西妥昔单抗联合卡培他滨和伊立替康与西妥昔单抗联合卡培他滨和奥沙利铂作为转移性结直肠癌患者的一线治疗：AIO KRK-0104-德国AIO CRC研究小组的一项随机试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205 [O] . T Hoehler, G von Wichert, C Schimanski, 2013

机译：卡培他滨和奥沙利铂联合贝伐单抗和伊马替尼治疗转移性结直肠癌的I / II期临床试验：AIO KRK 0205
7. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Teschendorf Christian, Sieber Markus, Denzlinger Claudio, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验

Phase I|[sol]|II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

摘要

著录项

相似文献

相关主题

期刊订阅